Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes

Journal of the American College of Cardiology

Volumn 71, Issue 21, 2018, Pages 2392-2401

  Everett, Brendan M ^a,b   Donath, Marc Y ^c   Pradhan, Aruna D ^a,d   Thuren, Tom ^e   Pais, Prem ^f   Nicolau, Jose C ^g   Glynn, Robert J ^a   Libby, Peter ^b   Ridker, Paul M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d BOSTON MEDICAL CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cardiovascular disease; diabetes; inflammation; randomized trial

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; PLACEBO; ANTIINFLAMMATORY AGENT; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MANAGEMENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; MALE; METABOLISM; MIDDLE AGED;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 85045342232     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.03.002     Document Type: Article

References (30)

1. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., Ridker, P.M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001), 327–334.
2. Donath, M.Y., Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13 (2014), 465–476.
3. Goldfine, A.B., Shoelson, S.E., Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest 127 (2017), 83–93.
4. Maedler, K., Sergeev, P., Ris, F., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110 (2002), 851–860.
5. Boni-Schnetzler, M., Thorne, J., Parnaud, G., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 93 (2008), 4065–4074.
6. Masters, S.L., Dunne, A., Subramanian, S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11 (2010), 897–904.
7. Maedler, K., Spinas, G.A., Lehmann, R., et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50 (2001), 1683–1690.
8. Larsen, C.M., Faulenbach, M., Vaag, A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356 (2007), 1517–1526.
9. Larsen, C.M., Faulenbach, M., Vaag, A., Ehses, J.A., Donath, M.Y., Mandrup-Poulsen, T., Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32 (2009), 1663–1668.
10. Cavelti-Weder, C., Babians-Brunner, A., Keller, C., et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35 (2012), 1654–1662.
11. Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 36 (2013), 2239–2246.
12. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37 Suppl 1 (2014), S81–S90.
14. Ridker, P.M., MacFadyen, J.G., Thuren, T., et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390 (2017), 1833–1842.
15. Ridker, P.M., MacFadyen, J.G., Everett, B.M., et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391 (2018), 319–328.
16. Ridker, P.M., Pradhan, A., MacFadyen, J.G., Libby, P., Glynn, R.J., Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380 (2012), 565–571.
17. Ridker, P.M., Howard, C.P., Walter, V., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126 (2012), 2739–2748.
18. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
19. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
20. Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993), 87–91.
21. Ofei, F., Hurel, S., Newkirk, J., Sopwith, M., Taylor, R., Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45 (1996), 881–885.
22. Dominguez, H., Storgaard, H., Rask-Madsen, C., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42 (2005), 517–525.
23. Bernstein, L.E., Berry, J., Kim, S., Canavan, B., Grinspoon, S.K., Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166 (2006), 902–908.
24. Goldfine, A.B., Fonseca, V., Jablonski, K.A., et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 159 (2013), 1–12.
25. Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J Clin Invest 116 (2006), 1793–1801.
26. Everett, B.M., Pradhan, A.D., Solomon, D.H., et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166 (2013), 199–207.e15.
27. Stability Investigators, White, H.D., Held, C., Stewart, R., et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370 (2014), 1702–1711.
28. O'Donoghue, M.L., Glaser, R., Cavender, M.A., et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315 (2016), 1591–1599.
29. Stern, M.P., Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 44 (1995), 369–374.
30. Ridker, P.M., Wilson, P.W., Grundy, S.M., Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004), 2818–2825.